来自专业的译者、企业、网页和免费的翻译库。
japansk encephalitisvirus
japanese encephalitis virus;
最后更新: 2014-11-21
使用频率: 2
质量:
effektmålet var vaccinens evne til at udløse produktionen af antistoffer mod japansk encephalitisvirus fire uger efter den sidste injektion.
the measure of effectiveness was the ability of the vaccine to trigger the production of antibodies against the japanese encephalitis virus, four weeks after the final injection.
efterfølgende vil immunsystemet være i stand til hurtigere og i store mængder at danne antistoffer, når det udsættes for japansk encephalitisvirus.
in future, the immune system will be able to produce antibodies quickly and in large numbers when it is exposed to japanese encephalitis virus.
vaccination med ixiaro bør overvejes af personer, som har risiko for at blive udsat for japansk encephalitisvirus via rejser eller arbejde.
vaccination with ixiaro should be considered for people who are at risk of exposure to the japanese encephalitis virus through travel or work.
de supplerende undersøgelser viste, at beskyttelsen mod japansk encephalitisvirus varede mindst to- tre år hos størsteparten af de mennesker, der var vaccineret med ixiaro.
the additional studies showed that protection against japanese encephalitis virus lasted for at least two to three years in most people vaccinated with ixiaro.
hos voksne var ixiaro (givet som to doser med fire ugers mellemrum) lige så effektivt som sammenligningsvaccinen til at udløse produktionen af antistoffer mod japansk encephalitisvirus.
in adults, ixiaro (given as two doses 4 weeks apart) was as effective as the comparator vaccine at triggering the production of antibodies against the japanese encephalitis virus.
voksne mellem 18-65 år, der forventes at blive udsat for japansk encephalitisvirus igen, eller som konstant har risiko for at få sygdommen, bør modtage en boosterdosis af ixiaro et eller to år senere og en anden boosterdosis 10 år efter den første booster.
adults from 18-65 years who are likely to be exposed to the japanese encephalitis virus again or who are at continuous risk of the disease should receive a booster dose of ixiaro one to two years later and a second booster dose 10 years after the first booster.